Literature DB >> 27362390

Comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies for pharmacological cardioversion of short‑duration atrial fibrillation in the emergency department.

Michał M Farkowski, Aleksander Maciąg, Małgorzata Żurawska, Mariusz Pytkowski, Ilona Kowalik, Jacek Woźniak, Maciej Sterliński, Hanna Szwed.   

Abstract

INTRODUCTION    Numerous studies described the effectiveness and safety of antazoline in pharmacological cardioversion of short‑duration atrial fibrillation (AF). However, there are no data on the comparison of antazoline and antiarrhythmic drugs listed in clinical guidelines. OBJECTIVES    The aim of the study was to assess the comparative effectiveness and safety of antazoline‑based and propafenone‑based strategies in pharmacological cardioversion of short‑duration AF performed in our emergency department. PATIENTS AND METHODS    We conducted a retrospective case‑control study based on the analysis of medical records of patients undergoing pharmacological cardioversion of short‑duration AF with intravenous antazoline or propafenone at our department in the years 2008-2012. The primary endpoint was the successful cardioversion of AF. The primary safety endpoint was hospitalization due to the adverse effects of the treatment. RESULTS    We analyzed 432 cases of cardioversion. The mean age of patients was 68.9 ±9.8 years; 65% of the patients were male; 90% of the patients had a history of AF. Antazoline was administered 334 times and propafenone-98 times. The mean dose of antazoline was 172 ±65 mg, while all patients in the propafenone group received the drug at a fixed dose of 70 mg (1 vial). Cardioversion with antazoline was successful in 239 cases (71.6%) and with propafenone-in 54 patients (55.1%) (relative risk [RR], 1.30; 95% confidence interval [CI], 1.07-1.57). The rate of hospitalization due to the adverse effects of the treatment were low and similar between the study groups: 10 (3.0%) for antazoline and 4 (4.1%) for propafenone (RR, 0.73; 95% CI, 0.23-2.27). CONCLUSIONS    The antazoline‑based strategy was more effective and safer in comparison with propafenone‑based strategy in the pharmacological cardioversion of short‑duration AF in our emergency department.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27362390     DOI: 10.20452/pamw.3452

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  8 in total

1.  Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Ilona Kowalik; Marek Konka; Hanna Szwed; Mariusz Pytkowski
Journal:  Br J Clin Pharmacol       Date:  2019-05-23       Impact factor: 4.335

2.  Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy.

Authors:  Roman Piotrowski; Joanna Giebułtowicz; Jakub Baran; Agnieszka Sikorska; Dagmara Gralak-Łachowska; Małgorzata Soszyńska; Piotr Wroczyński; Piotr Kułakowski
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-02-25       Impact factor: 1.468

3.  Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart.

Authors:  Bartłomiej Jacek Bińkowski; Marcin Makowski; Paweł Kubiński; Andrzej Lubiński
Journal:  Cardiovasc Drugs Ther       Date:  2018-04       Impact factor: 3.727

4.  Characterization of In Vitro and In Vivo Metabolism of Antazoline Using Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Joanna Giebułtowicz; Natalia Korytowska; Roman Piotrowski; Piotr Kułakowski; Gniewomir Latacz; Ewa Szymańska; Barbara Wiśniowska; Sebastian Polak
Journal:  Int J Mol Sci       Date:  2020-12-18       Impact factor: 5.923

5.  Magnetic Core-Shell Molecularly Imprinted Nano-Conjugates for Extraction of Antazoline and Hydroxyantazoline from Human Plasma-Material Characterization, Theoretical Analysis and Pharmacokinetics.

Authors:  Joanna Giebułtowicz; Natalia Korytowska; Monika Sobiech; Sebastian Polak; Barbara Wiśniowska; Roman Piotrowski; Piotr Kułakowski; Piotr Luliński
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

6.  Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II Study.

Authors:  Beata Ceynowa-Sielawko; Maciej T Wybraniec; Aleksandra Topp-Zielińska; Aleksander Maciąg; Dawid Miśkowiec; Paweł Balsam; Maciej Wójcik; Wojciech Wróbel; Michał M Farkowski; Edyta Ćwiek-Rębowska; Krzysztof Ozierański; Robert Błaszczyk; Karolina Bula; Tomasz Dembowski; Michał Peller; Bartosz Krzowski; Wojciech Wańha; Marek Koziński; Jarosław D Kasprzak; Hanna Szwed; Katarzyna Mizia-Stec; Marek Szołkiewicz
Journal:  Int J Environ Res Public Health       Date:  2022-04-17       Impact factor: 3.390

7.  Pharmacological Cardioversion With Antazoline in Atrial Fibrillation: The Results of the CANT Study.

Authors:  Maciej T Wybraniec; Wojciech Wróbel; Katarzyna Wilkosz; Karolina Wrona; Karolina Bula; Katarzyna Mizia-Stec
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

8.  Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating.

Authors:  Barbara Wiśniowska; Joanna Giebułtowicz; Roman Piotrowski; Piotr Kułakowski; Sebastian Polak
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.